An open-label safety study of first-line bevacizumab in combination with standard chemotherapy in Chinese patients with metastatic colorectal cancer treated in an expanded access program in Taiwan

Kuan Der Lee, Hong Hwa Chen, Hwei Ming Wang, Chao Jung Tsao, Tzu Chi Hsu, Chang Fang Chiu, Wu Chou Su, Jeng Yi Wang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: An increased risk of serious adverse effects related to bevacizumab has been observed in many Western studies for metastatic colorectal cancer. To evaluate the safety of bevacizumab in Chinese patients, a safety study was conducted in Taiwan. Methods: Bevacizumab was provided by the Expanded Access Program in combination with first-line chemotherapy per investigator's choice. The primary objective is the safety profile, particularly the targeted adverse events such as proteinuria, bowel perforation, hypertension, wound healing complication, thromboembolism and bleeding. The second objectives include time to disease progression and overall survival time. Patients with major surgical procedure performed within the 28 days of bevacizumab were excluded from this study. Results: Forty patients were eligible for intent-to-treat analysis. The overall rate of objective response and disease control was 55.2 and 81.6%. The median time to disease progression and overall survival were 11.9 and 22.9 months. The actuarial 2-year survival was 46.6%. Regarding toxicity, 7 subjects (17.5%) had serious adverse effects related to study treatment. None of the patients in this cohort had arterial thrombotic events and bowel perforation. Conclusions: Bevacizumab demonstrates a similar activity and safety profile in Chinese patients. Life-threatening bowel complications were avoided in this study by excluding patients with major surgery within the first 28 days.

Original languageEnglish
Pages (from-to)299-304
Number of pages6
JournalOncology (Switzerland)
Volume84
Issue number5
DOIs
Publication statusPublished - May 2013
Externally publishedYes

Fingerprint

Taiwan
Colorectal Neoplasms
Safety
Drug Therapy
Survival
Disease Progression
Thromboembolism
Patient Safety
Proteinuria
Wound Healing
Research Personnel
Bevacizumab
Hemorrhage
Hypertension
Therapeutics

Keywords

  • Adverse effect
  • Bevacizumab
  • Colorectal cancer
  • Expanded Access Program

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

An open-label safety study of first-line bevacizumab in combination with standard chemotherapy in Chinese patients with metastatic colorectal cancer treated in an expanded access program in Taiwan. / Lee, Kuan Der; Chen, Hong Hwa; Wang, Hwei Ming; Tsao, Chao Jung; Hsu, Tzu Chi; Chiu, Chang Fang; Su, Wu Chou; Wang, Jeng Yi.

In: Oncology (Switzerland), Vol. 84, No. 5, 05.2013, p. 299-304.

Research output: Contribution to journalArticle

Lee, Kuan Der ; Chen, Hong Hwa ; Wang, Hwei Ming ; Tsao, Chao Jung ; Hsu, Tzu Chi ; Chiu, Chang Fang ; Su, Wu Chou ; Wang, Jeng Yi. / An open-label safety study of first-line bevacizumab in combination with standard chemotherapy in Chinese patients with metastatic colorectal cancer treated in an expanded access program in Taiwan. In: Oncology (Switzerland). 2013 ; Vol. 84, No. 5. pp. 299-304.
@article{def7bc2b2ab94ddcaf7bd223a5b7c7c2,
title = "An open-label safety study of first-line bevacizumab in combination with standard chemotherapy in Chinese patients with metastatic colorectal cancer treated in an expanded access program in Taiwan",
abstract = "Objective: An increased risk of serious adverse effects related to bevacizumab has been observed in many Western studies for metastatic colorectal cancer. To evaluate the safety of bevacizumab in Chinese patients, a safety study was conducted in Taiwan. Methods: Bevacizumab was provided by the Expanded Access Program in combination with first-line chemotherapy per investigator's choice. The primary objective is the safety profile, particularly the targeted adverse events such as proteinuria, bowel perforation, hypertension, wound healing complication, thromboembolism and bleeding. The second objectives include time to disease progression and overall survival time. Patients with major surgical procedure performed within the 28 days of bevacizumab were excluded from this study. Results: Forty patients were eligible for intent-to-treat analysis. The overall rate of objective response and disease control was 55.2 and 81.6{\%}. The median time to disease progression and overall survival were 11.9 and 22.9 months. The actuarial 2-year survival was 46.6{\%}. Regarding toxicity, 7 subjects (17.5{\%}) had serious adverse effects related to study treatment. None of the patients in this cohort had arterial thrombotic events and bowel perforation. Conclusions: Bevacizumab demonstrates a similar activity and safety profile in Chinese patients. Life-threatening bowel complications were avoided in this study by excluding patients with major surgery within the first 28 days.",
keywords = "Adverse effect, Bevacizumab, Colorectal cancer, Expanded Access Program",
author = "Lee, {Kuan Der} and Chen, {Hong Hwa} and Wang, {Hwei Ming} and Tsao, {Chao Jung} and Hsu, {Tzu Chi} and Chiu, {Chang Fang} and Su, {Wu Chou} and Wang, {Jeng Yi}",
year = "2013",
month = "5",
doi = "10.1159/000347228",
language = "English",
volume = "84",
pages = "299--304",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "5",

}

TY - JOUR

T1 - An open-label safety study of first-line bevacizumab in combination with standard chemotherapy in Chinese patients with metastatic colorectal cancer treated in an expanded access program in Taiwan

AU - Lee, Kuan Der

AU - Chen, Hong Hwa

AU - Wang, Hwei Ming

AU - Tsao, Chao Jung

AU - Hsu, Tzu Chi

AU - Chiu, Chang Fang

AU - Su, Wu Chou

AU - Wang, Jeng Yi

PY - 2013/5

Y1 - 2013/5

N2 - Objective: An increased risk of serious adverse effects related to bevacizumab has been observed in many Western studies for metastatic colorectal cancer. To evaluate the safety of bevacizumab in Chinese patients, a safety study was conducted in Taiwan. Methods: Bevacizumab was provided by the Expanded Access Program in combination with first-line chemotherapy per investigator's choice. The primary objective is the safety profile, particularly the targeted adverse events such as proteinuria, bowel perforation, hypertension, wound healing complication, thromboembolism and bleeding. The second objectives include time to disease progression and overall survival time. Patients with major surgical procedure performed within the 28 days of bevacizumab were excluded from this study. Results: Forty patients were eligible for intent-to-treat analysis. The overall rate of objective response and disease control was 55.2 and 81.6%. The median time to disease progression and overall survival were 11.9 and 22.9 months. The actuarial 2-year survival was 46.6%. Regarding toxicity, 7 subjects (17.5%) had serious adverse effects related to study treatment. None of the patients in this cohort had arterial thrombotic events and bowel perforation. Conclusions: Bevacizumab demonstrates a similar activity and safety profile in Chinese patients. Life-threatening bowel complications were avoided in this study by excluding patients with major surgery within the first 28 days.

AB - Objective: An increased risk of serious adverse effects related to bevacizumab has been observed in many Western studies for metastatic colorectal cancer. To evaluate the safety of bevacizumab in Chinese patients, a safety study was conducted in Taiwan. Methods: Bevacizumab was provided by the Expanded Access Program in combination with first-line chemotherapy per investigator's choice. The primary objective is the safety profile, particularly the targeted adverse events such as proteinuria, bowel perforation, hypertension, wound healing complication, thromboembolism and bleeding. The second objectives include time to disease progression and overall survival time. Patients with major surgical procedure performed within the 28 days of bevacizumab were excluded from this study. Results: Forty patients were eligible for intent-to-treat analysis. The overall rate of objective response and disease control was 55.2 and 81.6%. The median time to disease progression and overall survival were 11.9 and 22.9 months. The actuarial 2-year survival was 46.6%. Regarding toxicity, 7 subjects (17.5%) had serious adverse effects related to study treatment. None of the patients in this cohort had arterial thrombotic events and bowel perforation. Conclusions: Bevacizumab demonstrates a similar activity and safety profile in Chinese patients. Life-threatening bowel complications were avoided in this study by excluding patients with major surgery within the first 28 days.

KW - Adverse effect

KW - Bevacizumab

KW - Colorectal cancer

KW - Expanded Access Program

UR - http://www.scopus.com/inward/record.url?scp=84875671939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875671939&partnerID=8YFLogxK

U2 - 10.1159/000347228

DO - 10.1159/000347228

M3 - Article

VL - 84

SP - 299

EP - 304

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 5

ER -